DE69638122D1
(de)
*
|
1996-09-04 |
2010-03-18 |
Intertrust Tech Corp |
Zuverlässige Infrastrukturhilfssysteme, Verfahren und Techniken für sicheren elektronischen Handel, elektronische Transaktionen, Handelsablaufsteuerung und Automatisierung, verteilte Verarbeitung und Rechteverwaltung
|
US6184226B1
(en)
*
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
CA2699568C
(fr)
|
1999-12-24 |
2013-03-12 |
Aventis Pharma Limited |
Azaindoles
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
CA2422371C
(fr)
|
2000-09-15 |
2010-05-18 |
Vertex Pharmaceuticals Incorporated |
Composes de pyrazole utiles comme inhibiteurs de proteine kinase
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US7105532B2
(en)
*
|
2000-12-19 |
2006-09-12 |
Smithkline Beecham Corporation |
Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
|
US20030105090A1
(en)
*
|
2000-12-21 |
2003-06-05 |
David Bebbington |
Pyrazole compounds useful as protein kinase inhibitors
|
IL156306A0
(en)
*
|
2000-12-21 |
2004-01-04 |
Glaxo Group Ltd |
Pyrimidineamines as angiogenesis modulators
|
WO2002079163A1
(fr)
*
|
2001-03-30 |
2002-10-10 |
Smithkline Beecham Corporation |
Derives d'aminopyridine utilises comme modulateurs de recepteurs des oestrogenes
|
WO2002092573A2
(fr)
*
|
2001-05-16 |
2002-11-21 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de src et autres proteine kinases
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
US20030176437A1
(en)
|
2001-08-31 |
2003-09-18 |
D.M. Watterson |
Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
|
WO2003030909A1
(fr)
*
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
|
EP1820503B1
(fr)
|
2001-09-26 |
2012-02-22 |
Pfizer Italia S.r.l. |
Dérivés d'aminoindazole actifs en tant qu'inhibiteurs de la kinase, leur procédé de préparation et compositions pharmaceutiques les contenant
|
TWI330183B
(fr)
*
|
2001-10-22 |
2010-09-11 |
Eisai R&D Man Co Ltd |
|
DE60236322D1
(de)
|
2001-12-07 |
2010-06-17 |
Vertex Pharma |
Verbindungen auf pyrimidin-basis als gsk-3-hemmer
|
SE0104140D0
(sv)
*
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
AU2002357164A1
(en)
|
2001-12-17 |
2003-06-30 |
Smithkline Beecham Corporation |
Pyrazolopyridazine derivatives
|
WO2003055866A1
(fr)
*
|
2001-12-21 |
2003-07-10 |
Bayer Pharmaceuticals Corporation |
Composes derives de quinazoline et de quinoline servant d'inhibiteurs de prolylpeptidase, d'inducteurs d'apoptose et d'agents therapeutiques anticancereux
|
US20030158195A1
(en)
|
2001-12-21 |
2003-08-21 |
Cywin Charles L. |
1,6 naphthyridines useful as inhibitors of SYK kinase
|
KR20040085151A
(ko)
|
2002-01-17 |
2004-10-07 |
뉴로젠 코포레이션 |
캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
CA2475633C
(fr)
*
|
2002-02-06 |
2013-04-02 |
Vertex Pharmaceuticals Incorporated |
Composes heteroaryles utiles en tant qu'inhibiteurs de gsk-3
|
US20040009981A1
(en)
*
|
2002-03-15 |
2004-01-15 |
David Bebbington |
Compositions useful as inhibitors of protein kinases
|
EP1485100B1
(fr)
*
|
2002-03-15 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Azinylaminoazoles utilises comme inhibiteurs de proteine kinases
|
EP1485381B8
(fr)
*
|
2002-03-15 |
2010-05-12 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
|
BR0309009A
(pt)
*
|
2002-04-05 |
2005-03-22 |
Boehringer Ingelheim Pharma |
Método para o tratamento de hipersecreção de muco
|
ATE457728T1
(de)
*
|
2002-05-01 |
2010-03-15 |
Vertex Pharma |
Kristallstruktur des aurora-2 proteins und dessen bindungstaschen
|
MXPA04011472A
(es)
|
2002-05-22 |
2005-02-14 |
Amgen Inc |
Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor.
|
JPWO2003104230A1
(ja)
*
|
2002-06-07 |
2005-10-06 |
協和醗酵工業株式会社 |
二環性ピリミジン誘導体
|
WO2003106455A1
(fr)
|
2002-06-14 |
2003-12-24 |
Applied Research Systems Ars Holding N.V. |
Derives de cyanure d'azole methylidene et leur utilisation comme modulateurs de proteine kinase
|
MY141867A
(en)
*
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
AU2003249369A1
(en)
|
2002-06-21 |
2004-01-06 |
Cellular Genomics, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
CA2492673A1
(fr)
*
|
2002-07-17 |
2004-01-22 |
Pharmacia Italia S.P.A. |
Derives de pyrazole heterobicycliques utilises comme inhibiteurs de kinase
|
CA2494367A1
(fr)
*
|
2002-07-25 |
2004-02-05 |
Scios Inc. |
Methodes pour ameliorer la fonction respiratoire au moyen d'inhibiteurs du tgf-.beta.
|
ES2445208T3
(es)
|
2002-07-29 |
2014-02-28 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
|
CN101037438A
(zh)
*
|
2002-08-02 |
2007-09-19 |
沃泰克斯药物股份有限公司 |
用作gsk-3的抑制剂的吡唑组合物
|
EP1739087A1
(fr)
*
|
2002-08-02 |
2007-01-03 |
Vertex Pharmaceuticals Incorporated |
Compositions comprenant des composés pyrazoles et leur utilisation comme inhibiteurs de gsk-3
|
US20060235021A1
(en)
*
|
2002-08-13 |
2006-10-19 |
Wesley Blackaby |
Phenylpyridazine derivatives as ligands for gaba receptors
|
PL375447A1
(en)
*
|
2002-08-14 |
2005-11-28 |
Vertex Pharmaceuticals Incorporated |
Protein kinase inhibitors and uses thereof
|
FR2844267B1
(fr)
*
|
2002-09-05 |
2008-02-15 |
Aventis Pharma Sa |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
NZ539193A
(en)
|
2002-09-05 |
2008-04-30 |
Aventis Pharma Sa |
Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
|
UA80295C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Pyrazolopyridines and using the same
|
JP2006503043A
(ja)
*
|
2002-09-10 |
2006-01-26 |
サイオス インク. |
TGFβ阻害剤
|
AU2003286876A1
(en)
|
2002-11-01 |
2004-06-07 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of jak and other protein kinases
|
EP1560824A1
(fr)
|
2002-11-05 |
2005-08-10 |
Vertex Pharmaceuticals Incorporated |
Composes utiles comme inhibiteurs de proteines jak et autres proteines kinase
|
EP2316831B1
(fr)
|
2002-11-21 |
2013-03-06 |
Novartis AG |
Dérivés de 2-(morpholin-4-yl)pyrimidine comme inhibiteurs de Phosphotidylinositol (PI) 3-kinase pour le traitement de cancers.
|
SI2316831T1
(sl)
*
|
2002-11-21 |
2013-07-31 |
Novartis Ag |
2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka
|
US7759336B2
(en)
|
2002-12-10 |
2010-07-20 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic compounds and medicinal use thereof
|
FR2848554A1
(fr)
*
|
2002-12-12 |
2004-06-18 |
Aventis Pharma Sa |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
EP1572200B1
(fr)
|
2002-12-12 |
2011-08-17 |
Aventis Pharma S.A. |
Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
|
MXPA05006123A
(es)
|
2002-12-13 |
2005-09-30 |
Neurogen Corp |
Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina.
|
US7601718B2
(en)
|
2003-02-06 |
2009-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
US7157455B2
(en)
*
|
2003-02-10 |
2007-01-02 |
Hoffmann-La Roche Inc. |
4-Aminopyrimidine-5-one derivatives
|
JP2006521398A
(ja)
*
|
2003-03-28 |
2006-09-21 |
サイオス・インコーポレーテツド |
TGFβの二−環式ピリミジン阻害剤
|
WO2004092196A2
(fr)
*
|
2003-04-09 |
2004-10-28 |
Exelixis, Inc. |
Modulateurs de tie-2 et procedes d'utilisation
|
CN1809351A
(zh)
*
|
2003-04-24 |
2006-07-26 |
麦克公司 |
Akt活性抑制剂
|
WO2004096808A1
(fr)
*
|
2003-04-28 |
2004-11-11 |
De Novo Pharmaceuticals Limited |
Composes de triazine et leur utilisation
|
EP1633351A1
(fr)
*
|
2003-06-13 |
2006-03-15 |
Arena Pharmaceuticals, Inc. |
Derives d'acide 2h-pyrazol-3- carboxylique substitues en 5 utilises comme agonistes du recepteur de l'acide nicotinique rup25 pour le traitement des dyslipidemies et des pathologies apparentees
|
CA2528774A1
(fr)
*
|
2003-06-20 |
2005-01-27 |
Coley Pharmaceutical Gmbh |
Antagonistes des recepteurs toll (tlr) pour petites molecules
|
TW200510373A
(en)
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
US7329664B2
(en)
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
PL2256106T3
(pl)
|
2003-07-22 |
2015-08-31 |
Astex Therapeutics Ltd |
Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
|
KR101201603B1
(ko)
|
2003-07-30 |
2012-11-14 |
리겔 파마슈티칼스, 인크. |
자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
|
CN1894222A
(zh)
*
|
2003-08-05 |
2007-01-10 |
沃泰克斯药物股份有限公司 |
作为电压门控离子通道抑制剂的稠合嘧啶化合物
|
US7226920B2
(en)
*
|
2003-08-06 |
2007-06-05 |
Vertex Pharmaceuticals Inc. |
Aminotriazole compounds useful as inhibitors of protein kinases
|
CA2539549A1
(fr)
*
|
2003-09-23 |
2005-04-07 |
Vertex Pharmaceuticals Incorporated |
Derives de pyrazolopyrrole utilises en tant qu'inhibiteurs de proteines kinases
|
GB0323137D0
(en)
|
2003-10-03 |
2003-11-05 |
Chang Lisa C W |
2,4,6- Trisubstituted pyrimidines and their different uses
|
EP1678169B1
(fr)
*
|
2003-10-17 |
2009-07-22 |
Astrazeneca AB |
Derives de 4-(pyrazol-3-ylamino) pyrimidine qui s'utilisent dans le traitement du cancer
|
US8455489B2
(en)
*
|
2003-11-10 |
2013-06-04 |
Exelixis, Inc. |
Substituted pyrimidine compositions and methods of use
|
AU2004289304A1
(en)
*
|
2003-11-10 |
2005-05-26 |
Synta Pharmaceuticals, Corp. |
Pyridine compounds
|
NZ546057A
(en)
*
|
2003-12-03 |
2010-04-30 |
Ym Bioscience Australia Pty Lt |
Tubulin inhibitors
|
CA2548172A1
(fr)
*
|
2003-12-04 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Quinoxalines utiles comme inhibiteurs des proteines kinases
|
AU2004297241A1
(en)
*
|
2003-12-09 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Naphthyridine derivatives and their use as modulators of muscarinic receptors
|
EP1694686A1
(fr)
*
|
2003-12-19 |
2006-08-30 |
Takeda San Diego, Inc. |
Inhibiteurs de kinase
|
TW200530235A
(en)
|
2003-12-24 |
2005-09-16 |
Renovis Inc |
Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
|
BRPI0507373A
(pt)
|
2004-01-23 |
2007-07-10 |
Amgen Inc |
compostos e método de uso
|
WO2005073224A2
(fr)
|
2004-01-23 |
2005-08-11 |
Amgen Inc |
Composes et methodes d'utilisation de ces derniers
|
US7534798B2
(en)
|
2004-02-11 |
2009-05-19 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
CA2561718A1
(fr)
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Pyridines polycycliques constituant des modulateurs de canaux ioniques potassiques
|
JP2007533753A
(ja)
*
|
2004-04-23 |
2007-11-22 |
タケダ サン ディエゴ インコーポレイテッド |
インドール誘導体及びキナーゼ阻害剤としてのその使用
|
US7793137B2
(en)
|
2004-10-07 |
2010-09-07 |
Cisco Technology, Inc. |
Redundant power and data in a wired data telecommunincations network
|
MXPA06013042A
(es)
|
2004-05-14 |
2007-02-12 |
Millennium Pharm Inc |
Compuestos y m??todos para inhibir la progresion mit??tica.
|
EP1604988A1
(fr)
*
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Dérivés de pyridazinone, méthodes de leur préparation et leur utilisation comme pharmaceutiques
|
EP1598348A1
(fr)
|
2004-05-18 |
2005-11-23 |
Aventis Pharma Deutschland GmbH |
Dérivés de pyridazinone comme inhibiteurs de CDK2
|
DE102004028862A1
(de)
*
|
2004-06-15 |
2005-12-29 |
Merck Patent Gmbh |
3-Aminoindazole
|
GB0415364D0
(en)
*
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
US20080261821A1
(en)
*
|
2004-07-21 |
2008-10-23 |
The Regents Of Te University Of California |
Mechanism-Based Crosslinkers
|
EP1778669A2
(fr)
*
|
2004-08-18 |
2007-05-02 |
Takeda San Diego, Inc. |
Inhibiteurs de kinase
|
ATE502931T1
(de)
|
2004-08-19 |
2011-04-15 |
Dsm Ip Assets Bv |
Verfahren zur rektifikation von vitamin e acetat
|
GB0419416D0
(en)
|
2004-09-01 |
2004-10-06 |
Inst Of Ex Botany Ascr |
4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
|
CA2579143A1
(fr)
|
2004-09-13 |
2006-03-23 |
Amgen Inc. |
Ligands du recepteur vanilloide et leur utilisation dans des traitements
|
EP1796673A2
(fr)
*
|
2004-09-23 |
2007-06-20 |
Reddy US Therapeutics, Inc. |
Nouveaux composes de pyrimidine, leur procede de preparation, et compositions les contenant
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
TW200624431A
(en)
|
2004-09-24 |
2006-07-16 |
Hoffmann La Roche |
Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
|
AR052771A1
(es)
|
2004-09-30 |
2007-04-04 |
Tibotec Pharm Ltd |
Pirimidinas biciclicas inhibidoras del vhc
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
WO2006044687A2
(fr)
*
|
2004-10-15 |
2006-04-27 |
Takeda San Diego, Inc. |
Inhibiteurs de kinase
|
TW200621257A
(en)
*
|
2004-10-20 |
2006-07-01 |
Astellas Pharma Inc |
Pyrimidine derivative fused with nonaromatic ring
|
WO2006050359A2
(fr)
|
2004-11-02 |
2006-05-11 |
Northwestern University |
Composes pyridazine et methodes
|
BRPI0517947A
(pt)
|
2004-11-02 |
2008-10-21 |
Univ Northwestern |
composto de piridazina, composições e métodos
|
WO2006055831A2
(fr)
*
|
2004-11-17 |
2006-05-26 |
Miikana Therapeutics, Inc. |
Inhibiteurs de kinase
|
EP1814878B1
(fr)
|
2004-11-24 |
2012-01-04 |
Rigel Pharmaceuticals, Inc. |
Composes de spiro-2, 4-pyrimidinediamine et leurs utilisations
|
EP1827434B1
(fr)
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Heterocycles substitues et leurs procedes d'utilisation
|
US20060128710A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Chih-Hung Lee |
Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
|
EP1831216A2
(fr)
*
|
2004-12-23 |
2007-09-12 |
Pfizer Products Inc. |
Derives heteroaromatiques utiles en tant qu'agents anticancereux
|
JP5208516B2
(ja)
*
|
2004-12-30 |
2013-06-12 |
エグゼリクシス, インコーポレイテッド |
キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
|
ATE451381T1
(de)
|
2005-01-19 |
2009-12-15 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
CN101146796A
(zh)
*
|
2005-01-26 |
2008-03-19 |
先灵公司 |
作为蛋白激酶抑制剂用于治疗癌症的3-(吲唑-5-基)-(1,2,4)三嗪衍生物及相关化合物
|
PL1846394T3
(pl)
|
2005-02-04 |
2012-04-30 |
Astrazeneca Ab |
Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
|
US20060178388A1
(en)
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
KR101362621B1
(ko)
|
2005-02-16 |
2014-02-13 |
아스트라제네카 아베 |
화합물
|
JP2008534481A
(ja)
*
|
2005-03-23 |
2008-08-28 |
アストラゼネカ アクチボラグ |
インスリン様増殖因子−1受容体活性の阻害剤としての2−アゼチジニル−4−(1h−ピラゾール−3−イルアミノ)ピリミジン
|
US7402596B2
(en)
|
2005-03-24 |
2008-07-22 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
BRPI0609650A2
(pt)
|
2005-03-25 |
2010-04-20 |
Tibotec Pharm Ltd |
inibidores heterobicìlicos de hvc
|
JP2008534662A
(ja)
*
|
2005-04-05 |
2008-08-28 |
アストラゼネカ アクチボラグ |
抗癌剤として使用されるピリミジン誘導体
|
GB0507347D0
(en)
*
|
2005-04-12 |
2005-05-18 |
Astrazeneca Ab |
Chemical compounds
|
WO2006108489A1
(fr)
|
2005-04-14 |
2006-10-19 |
F. Hoffmann-La Roche Ag |
Derives aminopyrazole, leur fabrication et leur utilisation comme agents pharmaceutiques
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
AU2006241825A1
(en)
|
2005-04-28 |
2006-11-09 |
Mitsubishi Tanabe Pharma Corporation |
Cyanopyridine derivative and use thereof as medicine
|
US20080207594A1
(en)
|
2005-05-04 |
2008-08-28 |
Davelogen Aktiengesellschaft |
Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
|
ES2552804T3
(es)
|
2005-05-04 |
2015-12-02 |
Evotec Ag |
Compuestos heterocíclicos condensados, y sus composiciones y usos
|
US20080194606A1
(en)
*
|
2005-05-05 |
2008-08-14 |
Astrazeneca |
Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer
|
AR056347A1
(es)
|
2005-05-12 |
2007-10-03 |
Tibotec Pharm Ltd |
Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
|
AU2006248780B2
(en)
*
|
2005-05-16 |
2010-06-03 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
US8232278B2
(en)
|
2005-06-24 |
2012-07-31 |
Gilead Sciences, Inc. |
Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C
|
ES2270715B1
(es)
|
2005-07-29 |
2008-04-01 |
Laboratorios Almirall S.A. |
Nuevos derivados de pirazina.
|
ATE542814T1
(de)
*
|
2005-08-18 |
2012-02-15 |
Vertex Pharma |
Pyrazinkinaseinhibitoren
|
WO2007023382A2
(fr)
*
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Composes de pyrimidine amino pyrazole, puissants inhibiteurs de kinase
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス,インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
EP2258359A3
(fr)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
|
US7915286B2
(en)
|
2005-09-16 |
2011-03-29 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
ES2535854T3
(es)
*
|
2005-09-30 |
2015-05-18 |
Miikana Therapeutics, Inc. |
Compuestos de pirazol sustituidos
|
CN101316587B
(zh)
*
|
2005-09-30 |
2013-04-03 |
迈卡纳治疗股份有限公司 |
取代的吡唑化合物
|
ES2274712B1
(es)
|
2005-10-06 |
2008-03-01 |
Laboratorios Almirall S.A. |
Nuevos derivados imidazopiridina.
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
GB0520657D0
(en)
*
|
2005-10-11 |
2005-11-16 |
Ludwig Inst Cancer Res |
Pharmaceutical compounds
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
PT1945631E
(pt)
|
2005-10-28 |
2012-10-15 |
Astrazeneca Ab |
Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
|
CA2625210A1
(fr)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
|
BRPI0619708A2
(pt)
*
|
2005-11-03 |
2011-10-11 |
Vertex Pharma |
composto, composição, método para inibir a atividade da proteìna aurora quinase numa amostra biológica, método para tratar distúrbio proliferativo e método para tratar cáncer
|
HUE032640T2
(en)
|
2005-11-08 |
2017-10-30 |
Vertex Pharma |
Heterocyclic modulator of ATP-binding cassette transcripts
|
US7713987B2
(en)
|
2005-12-06 |
2010-05-11 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2,4-diamines and their uses
|
US8546404B2
(en)
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
US7572809B2
(en)
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
JP2009520825A
(ja)
*
|
2005-12-20 |
2009-05-28 |
武田薬品工業株式会社 |
グルコキナーゼ活性剤
|
AR060316A1
(es)
|
2006-01-17 |
2008-06-11 |
Vertex Pharma |
Azaindoles de utilidad como inhibidores de janus quinasas
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
WO2007097937A1
(fr)
|
2006-02-16 |
2007-08-30 |
Schering Corporation |
Nouveaux composés inhibiteurs erk
|
AU2007223036A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
PE20080145A1
(es)
|
2006-03-21 |
2008-02-11 |
Janssen Pharmaceutica Nv |
Tetrahidro-pirimidoazepinas como moduladores de trpv1
|
ES2376765T3
(es)
*
|
2006-04-11 |
2012-03-16 |
Vertex Pharmaceuticals, Inc. |
Tiazoles, imidazoles y pirazoles útiles como inhibidores de proteína quinasas
|
EP2015750A2
(fr)
|
2006-04-28 |
2009-01-21 |
Northwestern University |
Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinestérase
|
EP2377531A2
(fr)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogénèse par modulation de l'angiotensine
|
EP2026813A2
(fr)
*
|
2006-05-09 |
2009-02-25 |
Braincells, Inc. |
Neurogenèse induite par le récepteur 5ht
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
RS52307B
(en)
*
|
2006-06-27 |
2012-12-31 |
Takeda Pharmaceutical Company Limited |
CONDENSED CYCLIC UNITS
|
EP2044063A1
(fr)
*
|
2006-06-30 |
2009-04-08 |
Astra Zeneca AB |
Dérivés de pyrimidine utiles dans le traitement du cancer
|
US8222256B2
(en)
|
2006-07-05 |
2012-07-17 |
Exelixis, Inc. |
Methods of using IGFIR and ABL kinase modulators
|
ATE523499T1
(de)
*
|
2006-07-06 |
2011-09-15 |
Array Biopharma Inc |
Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
UA95641C2
(en)
*
|
2006-07-06 |
2011-08-25 |
Эррей Биофарма Инк. |
Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
US8338435B2
(en)
|
2006-07-20 |
2012-12-25 |
Gilead Sciences, Inc. |
Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
|
US7998971B2
(en)
*
|
2006-09-08 |
2011-08-16 |
Braincells Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
EP2066355A2
(fr)
*
|
2006-09-19 |
2009-06-10 |
Braincells, Inc. |
Combinaison comprenant un agent ppar et un deuxième agent neurogène pour le traitement d'une maladie du système nerveux central, pour augmenter la différentiation neuronale et pour augmenter la neurogenèse
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
JP2010505961A
(ja)
*
|
2006-10-09 |
2010-02-25 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
BRPI0719883A2
(pt)
|
2006-10-09 |
2015-05-05 |
Takeda Pharmaceutical |
Inibidores de quinase
|
US8642598B2
(en)
|
2006-10-21 |
2014-02-04 |
Abbvie Inc. |
Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
|
AU2007317435A1
(en)
*
|
2006-11-02 |
2008-05-15 |
Vertex Pharmaceuticals Incorporated |
Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
|
NZ577768A
(en)
*
|
2006-12-19 |
2012-01-12 |
Vertex Pharma |
Aminopyrimidines useful as inhibitors of protein kinases
|
US8637531B2
(en)
|
2006-12-26 |
2014-01-28 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyridmidines useful for treating viral infections
|
WO2008077649A1
(fr)
|
2006-12-26 |
2008-07-03 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines utiles pour traiter des infections virales
|
TW200840584A
(en)
|
2006-12-26 |
2008-10-16 |
Gilead Sciences Inc |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
WO2008098058A1
(fr)
|
2007-02-06 |
2008-08-14 |
Novartis Ag |
Inhibiteurs de la pi3-kinase et procédés de leur utilisation
|
WO2008100412A1
(fr)
*
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Dérivés de la pipéridine
|
EP2121633A2
(fr)
*
|
2007-02-12 |
2009-11-25 |
Merck & Co., Inc. |
Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées
|
TW200901975A
(en)
|
2007-03-05 |
2009-01-16 |
Kyowa Hakko Kogyo Kk |
Pharmaceutical composition
|
JP2010520887A
(ja)
*
|
2007-03-09 |
2010-06-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
蛋白キナーゼの阻害剤として有用なアミノピリジン
|
JP5393489B2
(ja)
*
|
2007-03-09 |
2014-01-22 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
蛋白キナーゼの阻害剤として有用なアミノピリミジン
|
ES2435997T3
(es)
*
|
2007-03-09 |
2013-12-26 |
Vertex Pharmaceuticals, Inc. |
Aminopirimidinas útiles como inhibidores de las proteínas cinasas
|
JP2010523700A
(ja)
|
2007-04-13 |
2010-07-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼインヒビターとして有用なアミノピリミジン
|
EP2155742A1
(fr)
*
|
2007-04-18 |
2010-02-24 |
AstraZeneca AB |
Dérivés de 5-aminopyrazol-3-yl-3h-imidazo[4,5-b]pyridine et leur utilisation pour le traitement du cancer
|
WO2008137621A1
(fr)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines servant d'inhibiteurs de kinases
|
MX2009011811A
(es)
*
|
2007-05-02 |
2010-01-14 |
Vertex Pharma |
Aminopirimidinas utiles como inhibidores de cinasa.
|
MX2009011810A
(es)
*
|
2007-05-02 |
2010-01-14 |
Vertex Pharma |
Tiazoles y pirazoles utiles como inhibidores de cinasa.
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
EP2152702B1
(fr)
*
|
2007-05-04 |
2011-08-24 |
AstraZeneca AB |
Dérivés d'amino-thiazolyl-pyrimidine et leur utilisation pour le traitement du cancer
|
US8969386B2
(en)
|
2007-05-09 |
2015-03-03 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
MX2009012719A
(es)
*
|
2007-05-24 |
2010-02-04 |
Vertex Pharma |
Tiazoles y pirazoles utiles como inhibidores de cinasa.
|
CA2683152A1
(fr)
*
|
2007-06-11 |
2008-12-18 |
Miikana Therapeutics, Inc. |
Composes pyrazole substitues
|
EP2166854A4
(fr)
*
|
2007-06-13 |
2012-05-16 |
Merck Sharp & Dohme |
Dérivés du triazole destinés au traitement de la maladie d'alzheimer et d'états associés
|
JP2010531316A
(ja)
|
2007-06-25 |
2010-09-24 |
エフ.ホフマン−ラ ロシュ アーゲー |
キナーゼ阻害剤としてのベンズイミダゾールアミド誘導体
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
US8377937B2
(en)
*
|
2007-07-05 |
2013-02-19 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
TWI450720B
(zh)
|
2007-07-05 |
2014-09-01 |
Array Biopharma Inc |
作為akt蛋白質激酶抑制劑之嘧啶環戊烷
|
EP2175933B1
(fr)
|
2007-07-25 |
2012-08-22 |
Bristol-Myers Squibb Company |
Inhibiteurs de triazine kinase
|
AR067762A1
(es)
*
|
2007-07-31 |
2009-10-21 |
Vertex Pharma |
Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
|
TW200906818A
(en)
*
|
2007-07-31 |
2009-02-16 |
Astrazeneca Ab |
Chemical compounds
|
WO2009067166A2
(fr)
*
|
2007-11-20 |
2009-05-28 |
Merck & Co., Inc. |
Inhibiteurs non-nucléosidiques de la transcriptase inverse
|
KR20100101130A
(ko)
|
2007-12-07 |
2010-09-16 |
버텍스 파마슈티칼스 인코포레이티드 |
3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
|
CA2707494C
(fr)
*
|
2007-12-07 |
2018-04-24 |
Vertex Pharmaceuticals Incorporated |
Procedes de fabrication d'acides cycloalkylcarboxamido-pyridine benzoiques
|
JP2011032169A
(ja)
*
|
2007-12-11 |
2011-02-17 |
Genecare Research Institute Co Ltd |
4−アミノピリミジン誘導体および該化合物を含有する医薬組成物
|
WO2009078999A1
(fr)
|
2007-12-17 |
2009-06-25 |
Janssen Pharmaceutica N.V. |
Modulateurs imidazolo-, oxazolo- et thiazolopyrimidines de trpv1
|
JP5635910B2
(ja)
*
|
2008-01-09 |
2014-12-03 |
アレイ バイオファーマ、インコーポレイテッド |
AKTタンパク質キナーゼ阻害剤としての5H−シクロペンタ[d]ピリミジン
|
PE20091315A1
(es)
|
2008-01-09 |
2009-09-21 |
Array Biopharma Inc |
Ciclopentanos de pirimidilo como inhibidores de la proteina cinasa akt
|
CA2714479A1
(fr)
|
2008-02-21 |
2009-08-27 |
Schering Corporation |
Composes inhibiteurs de la voie erk
|
NZ602030A
(en)
|
2008-02-28 |
2014-02-28 |
Vertex Pharma |
Heteroaryl derivatives as cftr modulators
|
EP2262498A2
(fr)
*
|
2008-03-10 |
2010-12-22 |
Vertex Pharmceuticals Incorporated |
Pyrimidines et pyridines utiles comme inhibiteurs des protéines kinases
|
CL2009000904A1
(es)
|
2008-04-21 |
2010-04-30 |
Shionogi & Co |
Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
|
US8158656B2
(en)
*
|
2008-05-16 |
2012-04-17 |
Shenzhen Chipscreen Biosciences Ltd. |
2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
DK2300013T3
(en)
|
2008-05-21 |
2017-12-04 |
Ariad Pharma Inc |
PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
|
WO2009150462A1
(fr)
*
|
2008-06-11 |
2009-12-17 |
Astrazeneca Ab |
Dérivés tricycliques de 2,4-diamino-l,3,5-triazine utiles pour le traitement du cancer et de troubles myéloprolifératifs
|
US8841287B2
(en)
|
2008-06-12 |
2014-09-23 |
Janssen Pharmaceutica N.V. |
Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
|
WO2010002998A1
(fr)
|
2008-07-03 |
2010-01-07 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines trisubstituées en position 2,4,6 utiles pour traiter des infections virales
|
CN102083831B
(zh)
*
|
2008-07-03 |
2014-09-03 |
默克专利有限公司 |
用作aurora激酶抑制剂的萘啶酮
|
KR20110046514A
(ko)
*
|
2008-07-31 |
2011-05-04 |
제넨테크, 인크. |
피리미딘 화합물, 조성물 및 사용 방법
|
EP2312945A4
(fr)
*
|
2008-08-13 |
2012-05-09 |
Merck Sharp & Dohme |
Dérivés de purine pour le traitement de la maladie d alzheimer
|
WO2010027921A1
(fr)
*
|
2008-09-03 |
2010-03-11 |
Vertex Pharmaceuticals Incorporated |
Co-cristaux et formulations pharmaceutiques les comprenant
|
CA2737388C
(fr)
*
|
2008-09-15 |
2017-07-11 |
Peter Walter |
Procedes et compositions pour moduler l'activite ire1, src, et abl
|
RU2011116928A
(ru)
*
|
2008-09-30 |
2012-11-20 |
Астразенека Аб (Se) |
Гетероциклические ингибиторы jак киназы
|
WO2010059610A1
(fr)
*
|
2008-11-19 |
2010-05-27 |
Renovis, Inc. |
Composés 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine s'utilisant comme modulateurs de la faah et utilisations desdits composés
|
KR101048448B1
(ko)
|
2008-11-21 |
2011-07-11 |
한국화학연구원 |
신규 피라졸로[4,3-b]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
|
EP3006031A1
(fr)
|
2009-02-05 |
2016-04-13 |
Takeda Pharmaceutical Company Limited |
Composés de pyridazinone
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
ES2456275T3
(es)
*
|
2009-02-27 |
2014-04-21 |
Ambit Biosciences Corporation |
Derivados de quinazolina moduladores de la quinasa JAK y su uso en métodos
|
JP2012519732A
(ja)
*
|
2009-03-09 |
2012-08-30 |
サーフェイス ロジックス,インコーポレイティド |
Rhoキナーゼ阻害剤
|
JP2012521425A
(ja)
*
|
2009-03-23 |
2012-09-13 |
Msd株式会社 |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
JP2012521427A
(ja)
*
|
2009-03-24 |
2012-09-13 |
Msd株式会社 |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
AU2010229140A1
(en)
*
|
2009-03-24 |
2011-11-10 |
Msd K.K. |
Novel aminopyridine derivatives having Aurora A selective inhibitory action
|
US8211901B2
(en)
|
2009-05-22 |
2012-07-03 |
Shenzhen Chipscreen Biosciences Ltd. |
Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
CN101906076B
(zh)
|
2009-06-04 |
2013-03-13 |
深圳微芯生物科技有限责任公司 |
作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
|
CN102573485B
(zh)
*
|
2009-06-08 |
2014-11-26 |
加利福尼亚资本权益有限责任公司 |
三嗪衍生物及其治疗应用
|
AU2010258853B2
(en)
|
2009-06-09 |
2014-07-31 |
Nantbio, Inc. |
Triazine derivatives and their therapeutical applications
|
BRPI1011527A2
(pt)
*
|
2009-06-09 |
2016-07-26 |
California Capital Equity Llc |
derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas.
|
US20100331305A1
(en)
*
|
2009-06-24 |
2010-12-30 |
Genentech, Inc. |
Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
|
US8637525B2
(en)
|
2009-07-31 |
2014-01-28 |
Bristol-Myers Squibb Company |
Compounds for the reduction of beta-amyloid production
|
TWI468402B
(zh)
*
|
2009-07-31 |
2015-01-11 |
必治妥美雅史谷比公司 |
降低β-類澱粉生成之化合物
|
US20110053916A1
(en)
*
|
2009-08-14 |
2011-03-03 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine compounds as tuberculosis inhibitors
|
CN102020657A
(zh)
*
|
2009-09-11 |
2011-04-20 |
上海艾力斯医药科技有限公司 |
稠合杂芳基衍生物、制备方法及其应用
|
CN102711766B
(zh)
|
2009-11-12 |
2014-06-04 |
霍夫曼-拉罗奇有限公司 |
N-9-取代的嘌呤化合物、组合物和使用方法
|
JP5572715B2
(ja)
*
|
2009-11-12 |
2014-08-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
N−7置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法
|
CA2789427A1
(fr)
*
|
2010-02-11 |
2011-08-18 |
Vanderbilt University |
Composes de pyrazolopyridine, de pyrazolopyrazine, de pyrazolopyrimidine, de pyrazolothiophene et de pyrazolothiazole en tant que potentialisateurs allosteriques du sous-type 4 durecepteur du glutamate metabotropique (mglur4), composes et procedes de traitement de dysfonctionnements neurologiques
|
LT3150198T
(lt)
|
2010-04-07 |
2021-12-10 |
Vertex Pharmaceuticals Incorporated |
3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
|
US8927547B2
(en)
|
2010-05-21 |
2015-01-06 |
Noviga Research Ab |
Pyrimidine derivatives
|
CA2797947C
(fr)
|
2010-06-04 |
2019-07-09 |
Charles Baker-Glenn |
Derives d'aminopyrimidine au titre de modulateurs de lrrk2
|
US20110319409A1
(en)
*
|
2010-06-23 |
2011-12-29 |
Cox Christopher D |
7-aza-quinazoline pde10 inhibitors
|
CN103298805A
(zh)
|
2010-09-01 |
2013-09-11 |
埃姆比特生物科学公司 |
喹唑啉化合物及其使用方法
|
CA2810954A1
(fr)
|
2010-09-27 |
2012-04-05 |
Abbott Gmbh & Co. Kg |
Composes heterocycliques et leur utilisation en tant qu'inhibiteurs de la glycogene synthase kinase-3
|
WO2012059932A1
(fr)
|
2010-11-01 |
2012-05-10 |
Aurigene Discovery Technologies Limited |
Dérivés de 2,4-diaminopyrimidine en tant qu'inhibiteurs de protéine kinases
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
HUE037844T2
(hu)
|
2010-11-10 |
2018-09-28 |
Genentech Inc |
Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
|
CA2818903C
(fr)
|
2010-12-14 |
2021-03-23 |
Electrophoretics Limited |
5-(1,3-benzoxazol-2-yl)-4-(pyridine-4-yl)pyrimidine-2-amine et son utilisation comme inhibiteur de caseine kinase 1 delta
|
CN103270026A
(zh)
|
2010-12-21 |
2013-08-28 |
诺瓦提斯公司 |
作为vps34抑制剂的联-杂芳基化合物
|
US9090592B2
(en)
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
WO2012101654A2
(fr)
*
|
2011-01-25 |
2012-08-02 |
Sphaera Pharma Pvt. Ltd |
Nouveaux composés de triazine
|
WO2012127032A1
(fr)
|
2011-03-24 |
2012-09-27 |
Chemilia Ab |
Nouveaux dérivés de pyrimidine
|
CN103874689B
(zh)
|
2011-04-01 |
2016-04-27 |
基因泰克公司 |
Akt抑制剂化合物和威罗菲尼的组合及使用方法
|
CN103841976A
(zh)
|
2011-04-01 |
2014-06-04 |
基因泰克公司 |
Akt和mek抑制剂化合物的组合及其使用方法
|
RU2477723C2
(ru)
|
2011-06-16 |
2013-03-20 |
Общество С Ограниченной Ответственностью "Фьюжн Фарма" |
Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
|
EP2734520B1
(fr)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Composés hétérocycliques et leurs utilisations
|
US8846656B2
(en)
|
2011-07-22 |
2014-09-30 |
Novartis Ag |
Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
|
RU2014109897A
(ru)
|
2011-08-25 |
2015-09-27 |
Ф.Хоффманн-Ля Рош Аг |
Ингибиторы серин/треонин киназы рак1
|
CN103929963A
(zh)
|
2011-09-14 |
2014-07-16 |
萨穆梅德有限公司 |
吲唑-3-羧酰胺及其作为WNT/β-CATENIN信号传导通路抑制剂的用途
|
JP5914667B2
(ja)
|
2011-09-22 |
2016-05-11 |
ファイザー・インク |
ピロロピリミジンおよびプリン誘導体
|
AU2012313888B2
(en)
|
2011-09-27 |
2016-03-31 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
|
BR112014015549A8
(pt)
|
2011-12-22 |
2017-07-04 |
Hoffmann La Roche |
composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
US9365556B2
(en)
*
|
2012-03-16 |
2016-06-14 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
EP2828250B1
(fr)
*
|
2012-03-19 |
2021-03-10 |
Imperial College Innovations Limited |
Composes de quinazoline et leur application therapeutque
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
RU2638540C1
(ru)
|
2012-04-24 |
2017-12-14 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы днк-пк
|
CN106279202A
(zh)
*
|
2012-05-03 |
2017-01-04 |
霍夫曼-拉罗奇有限公司 |
作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物
|
EP2844652B1
(fr)
*
|
2012-05-03 |
2019-03-13 |
Genentech, Inc. |
Dérivés de pyrazole aminopyrimidine en tant que modulateurs de lrrk2
|
AU2013280644B2
(en)
|
2012-06-26 |
2018-08-02 |
Jeffrey A. BACHA |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
|
EA030253B1
(ru)
|
2012-09-28 |
2018-07-31 |
Кэнсэр Ресерч Текнолоджи Лимитед |
Азахиназолиновые ингибиторы атипичной протеинкиназы c
|
JO3470B1
(ar)
|
2012-10-08 |
2020-07-05 |
Merck Sharp & Dohme |
مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
CN104955824B
(zh)
*
|
2012-11-20 |
2017-09-22 |
豪夫迈·罗氏有限公司 |
作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物
|
CA2892045C
(fr)
|
2012-11-21 |
2022-05-31 |
Ptc Therapeutics, Inc. |
Inhibiteurs de bmi-1 pyrimidines inverses substitues
|
CN103012428A
(zh)
|
2013-01-08 |
2013-04-03 |
中国药科大学 |
4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
|
JP6355648B2
(ja)
|
2013-01-08 |
2018-07-11 |
サミュメッド リミテッド ライアビリティ カンパニー |
Wntシグナル伝達経路の3−(ベンゾイミダゾール−2−イル)−インダゾール阻害剤およびそれらの治療的使用
|
TWI644899B
(zh)
|
2013-02-04 |
2018-12-21 |
健生藥品公司 |
Flap調節劑
|
US9745328B2
(en)
|
2013-02-04 |
2017-08-29 |
Janssen Pharmaceutica Nv |
Flap modulators
|
EP2769722A1
(fr)
*
|
2013-02-22 |
2014-08-27 |
Ruprecht-Karls-Universität Heidelberg |
Composés utilisés pour inhiber un assemblage de capside du VIH
|
JO3377B1
(ar)
*
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
HRP20211855T1
(hr)
|
2013-03-12 |
2022-03-04 |
Vertex Pharmaceuticals Incorporated |
Inhibitori dnk-pk
|
AP2015008707A0
(en)
|
2013-03-14 |
2015-09-30 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
WO2014153509A1
(fr)
|
2013-03-22 |
2014-09-25 |
Millennium Pharmaceuticals, Inc. |
Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a
|
CN112472699A
(zh)
|
2013-07-26 |
2021-03-12 |
种族肿瘤学公司 |
改善比生群及衍生物的治疗益处的组合方法
|
NZ748260A
(en)
|
2013-08-30 |
2020-01-31 |
Ptc Therapeutics Inc |
Substituted pyrimidine bmi-1 inhibitors
|
WO2015028848A1
(fr)
*
|
2013-09-02 |
2015-03-05 |
Piramal Enterprises Limited |
Composés hétérocycliques bicycliques utilisés comme inhibiteurs de plusieurs kinases
|
EP3052096B8
(fr)
|
2013-10-03 |
2018-03-07 |
Kura Oncology, Inc. |
Inhibiteurs d'erk et méthodes d'utilisation
|
WO2015054317A1
(fr)
*
|
2013-10-07 |
2015-04-16 |
Kadmon Corporation, Llc |
Inhibiteurs de la rho kinase
|
PL3424920T3
(pl)
|
2013-10-17 |
2020-11-16 |
Vertex Pharmaceuticals Incorporated |
Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
|
PT3068392T
(pt)
|
2013-11-12 |
2021-05-14 |
Vertex Pharma |
Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
US10584115B2
(en)
|
2013-11-21 |
2020-03-10 |
Ptc Therapeutics, Inc. |
Substituted pyridine and pyrazine BMI-1 inhibitors
|
US9975878B2
(en)
|
2013-11-21 |
2018-05-22 |
Ptc Therapeutics, Inc. |
Substituted triazine BMI-1 inhibitors
|
CN104672250B
(zh)
*
|
2013-11-29 |
2017-11-07 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
ES2813875T3
(es)
|
2014-01-01 |
2021-03-25 |
Medivation Tech Llc |
Compuestos y procedimientos de uso
|
WO2015112739A1
(fr)
*
|
2014-01-22 |
2015-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Composés et méthode de traitement de cancers à déficit en parp1
|
CN104926795B
(zh)
*
|
2014-03-17 |
2017-11-10 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
TWI675836B
(zh)
|
2014-03-25 |
2019-11-01 |
美商伊格尼塔公司 |
非典型蛋白質激酶c之氮雜喹唑啉抑制劑
|
CA2945263A1
(fr)
|
2014-04-09 |
2015-10-15 |
Christopher Rudd |
Utilisation d'inhibiteurs ou d'activateurs de gsk -3 qui modulent l'expression de pd -1 ou de t-bet pour moduler l'immunite due aux lymphocytes t
|
CN105367555B
(zh)
*
|
2014-08-07 |
2019-06-25 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
WO2016040184A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
|
WO2016040181A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
|
WO2016040180A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
|
WO2016040193A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
|
WO2016040185A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine et ses utilisations thérapeutiques
|
WO2016040190A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
|
HUE055423T2
(hu)
|
2014-11-18 |
2021-11-29 |
Vertex Pharma |
Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
|
TWI704151B
(zh)
*
|
2014-12-22 |
2020-09-11 |
美商美國禮來大藥廠 |
Erk抑制劑
|
JP6322770B2
(ja)
*
|
2014-12-22 |
2018-05-09 |
イーライ リリー アンド カンパニー |
Erk阻害剤
|
US10227343B2
(en)
|
2015-01-30 |
2019-03-12 |
Vanderbilt University |
Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
EP3070084A1
(fr)
*
|
2015-03-18 |
2016-09-21 |
Rottapharm Biotech S.r.l. |
Nouveaux inhibiteurs de la kinase fyn
|
US10752612B2
(en)
|
2015-04-17 |
2020-08-25 |
Ludwig Institute For Cancer Research Ltd |
PLK4 inhibitors
|
US10118904B2
(en)
|
2015-06-05 |
2018-11-06 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of Demyelinating Diseases
|
US10188634B2
(en)
|
2015-08-03 |
2019-01-29 |
Samumed, Llc |
3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10285982B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017024025A1
(fr)
|
2015-08-03 |
2017-02-09 |
Sunil Kumar Kc |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
WO2017023993A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
WO2017023984A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines et leurs utilisations thérapeutiques
|
US10392383B2
(en)
|
2015-08-03 |
2019-08-27 |
Samumed, Llc |
3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10604512B2
(en)
|
2015-08-03 |
2020-03-31 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
|
US10206909B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10329309B2
(en)
|
2015-08-03 |
2019-06-25 |
Samumed, Llc |
3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017023987A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques
|
WO2017024010A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
|
US10383861B2
(en)
|
2015-08-03 |
2019-08-20 |
Sammumed, LLC |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017023972A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
WO2017024003A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
KR20180080262A
(ko)
|
2015-11-06 |
2018-07-11 |
사뮤메드, 엘엘씨 |
골관절염의 치료
|
GB201604647D0
(en)
*
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
KR20190062485A
(ko)
|
2016-09-27 |
2019-06-05 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
|
WO2018075858A1
(fr)
|
2016-10-21 |
2018-04-26 |
Samumed, Llc |
PROCÉDÉS D'UTILISATION D'INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
|
JP7041141B2
(ja)
*
|
2016-11-01 |
2022-03-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
|
EP3534878A1
(fr)
|
2016-11-07 |
2019-09-11 |
Samumed, LLC |
Formulations injectables à dose unique prêtes à l'emploi
|
IT201700047189A1
(it)
*
|
2017-05-02 |
2018-11-02 |
Fondazione St Italiano Tecnologia |
Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
|
AR112027A1
(es)
*
|
2017-06-15 |
2019-09-11 |
Biocryst Pharm Inc |
Inhibidores de alk 2 quinasa que contienen imidazol
|
CN110573501B
(zh)
*
|
2017-06-30 |
2023-09-29 |
北京泰德制药股份有限公司 |
Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
|
JP7039802B2
(ja)
|
2017-06-30 |
2022-03-23 |
ベイジン タイド ファーマシューティカル カンパニー リミテッド |
Rho-関連プロテインキナーゼ阻害剤、rho-関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
|
CN117343049A
(zh)
|
2017-06-30 |
2024-01-05 |
北京泰德制药股份有限公司 |
Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
|
CN109384774B
(zh)
*
|
2017-08-11 |
2023-02-17 |
中国科学院上海药物研究所 |
一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
|
KR102613503B1
(ko)
|
2017-10-27 |
2023-12-13 |
세라밴스 바이오파마 알앤디 아이피, 엘엘씨 |
Jak 키나제 저해제로서 피리미딘 화합물
|
GB201801226D0
(en)
|
2018-01-25 |
2018-03-14 |
Redx Pharma Plc |
Modulators of Rho-associated protein kinase
|
US20220363648A1
(en)
*
|
2018-06-25 |
2022-11-17 |
Kadmon Corporation , Llc |
Glucose Uptake Inhibitors
|
WO2020045941A1
(fr)
*
|
2018-08-27 |
2020-03-05 |
주식회사 대웅제약 |
Nouveau dérivé d'amine hétérocyclique et composition pharmaceutique le comprenant
|
KR102328682B1
(ko)
*
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
WO2020139991A1
(fr)
|
2018-12-27 |
2020-07-02 |
Agios Pharmaceuticals, Inc. |
Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
|
CA3123902A1
(fr)
*
|
2019-01-03 |
2020-07-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Procedes et materiaux pour augmenter les niveaux de polypeptides eb de facteur de transcription
|
US20220133740A1
(en)
|
2019-02-08 |
2022-05-05 |
Frequency Therapeutics, Inc. |
Valproic acid compounds and wnt agonists for treating ear disorders
|
WO2020168197A1
(fr)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
WO2020198077A1
(fr)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
|
CN113518779B
(zh)
|
2019-03-28 |
2024-03-15 |
江苏恒瑞医药股份有限公司 |
噻吩并杂环类衍生物、其制备方法及其在医药上的应用
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
BR112021018924A2
(pt)
|
2019-03-29 |
2022-02-01 |
Jiangsu Hengrui Medicine Co |
Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
|
EP3959213A1
(fr)
|
2019-04-24 |
2022-03-02 |
Theravance Biopharma R&D IP, LLC |
Inhibiteurs de jak à base de pyrimidine pour le traitement de maladies de la peau
|
AR118768A1
(es)
|
2019-04-24 |
2021-10-27 |
Theravance Biopharma R&D Ip Llc |
Derivados de pirimidina como inhibidores de las cinasas jak
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
EP3978498A1
(fr)
|
2019-05-24 |
2022-04-06 |
Jiangsu Hengrui Medicine Co., Ltd. |
Dérivé bicyclicque condensé substituté, son procédé de préparation et son application en médecine
|
MA56047A
(fr)
*
|
2019-05-29 |
2022-04-06 |
Ifm Due Inc |
Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
|
MX2022001940A
(es)
|
2019-08-14 |
2022-05-10 |
Incyte Corp |
Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
|
JP2022547882A
(ja)
*
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Nlrp3阻害剤
|
US20230064948A1
(en)
*
|
2019-10-02 |
2023-03-02 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
PE20221905A1
(es)
|
2019-10-11 |
2022-12-23 |
Incyte Corp |
Aminas biciclicas como inhibidoras de la cdk2
|
EP4110778A1
(fr)
*
|
2020-02-26 |
2023-01-04 |
Jaguahr Therapeutics Pte Ltd |
Dérivés de pyridopyrimidine utiles dans la modulation de la signalisation de l'ahr
|
MX2023000521A
(es)
|
2020-07-15 |
2023-02-13 |
Chiesi Farm Spa |
Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5).
|
WO2022032484A1
(fr)
*
|
2020-08-11 |
2022-02-17 |
北京诺诚健华医药科技有限公司 |
Composé de pyridazine-3-formamide, son procédé de préparation et son utilisation médicale
|
WO2022068860A1
(fr)
|
2020-09-29 |
2022-04-07 |
江苏恒瑞医药股份有限公司 |
Forme cristalline d'un dérivé pyrrolo-hétérocyclique et son procédé de préparation
|
WO2022107919A1
(fr)
*
|
2020-11-19 |
2022-05-27 |
주식회사 보로노이 |
Dérivé d'hétéroaryle contenant du n et composition pharmaceutique pour la prévention ou le traitement de maladies associées aux protéines-kinases en comprenant en tant que principe actif
|
TW202317574A
(zh)
|
2021-06-28 |
2023-05-01 |
美商纜圖藥品公司 |
Cdk2抑制劑
|
TW202328102A
(zh)
|
2021-09-21 |
2023-07-16 |
義大利商吉斯藥品公司 |
作為alk5抑制劑之嗒𠯤基胺基衍生物
|
CN116023380B
(zh)
*
|
2021-10-26 |
2024-01-23 |
沈阳药科大学 |
一类吡唑并嘧啶衍生物及制备方法和应用
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
WO2023135107A1
(fr)
|
2022-01-11 |
2023-07-20 |
Chiesi Farmaceutici S.P.A. |
Dérivés pyridazinyl amino utilisés en tant qu'inhibiteurs d'alk5
|